8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 1, 2026·SEC
Curis, Inc.(CRIS)Earnings, Financials & Key Ratios
CRIS•NASDAQ
Price updated Jun 19, 2026
AboutCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$9M-13.4%
- EBITDA-$33M+26.2%
- Net Income-$8M+82.5%
- EPS (Diluted)-0.58+91.6%
- Gross Margin99.52%+0.4%
- EBITDA Margin-346.64%+14.7%
- Operating Margin-348.43%+14.7%
- Net Margin-80.29%+79.8%
- ROE-138.81%+78.1%
CRIS Key Insights
Curis, Inc. (CRIS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 24.0%
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 10.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRIS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRIS Price & Volume
Curis, Inc. (CRIS) stock price & volume — 10-year historical chart
Loading chart...
CRIS Growth Metrics
Curis, Inc. (CRIS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.83%
5 Years-2.71%
3 Years-2.42%
TTM-36.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM49.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.9%
Return on Capital
10 Years-82.35%
5 Years-95.79%
3 Years-137.21%
Last Year-233.94%
CRIS Recent Earnings
Curis, Inc. (CRIS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (36%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$1.25-331.0%
$0.29
Rev
—
$2M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.50-14.7%
$0.44
Rev
$1M-65.0%
$3M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.49+21.0%
$0.62
Rev
$3M+11.0%
$3M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.68+65.8%
$1.99
Rev
$3M-3.9%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.25vs $0.29-331.0% | —vs $2M |
| Q2 2026 | Mar 19, 2026 | $0.50vs $0.44-14.7% | $1Mvs $3M-65.0% |
| Q4 2025 | Nov 6, 2025 | $0.49vs $0.62+21.0% | $3Mvs $3M+11.0% |
| Q3 2025 | Aug 5, 2025 | $0.68vs $1.99+65.8% | $3Mvs $3M-3.9% |
Based on last 12 quarters of dataView full earnings history →
CRIS Peer Comparison
Curis, Inc. (CRIS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KPTI | 77.01M | 9.02 | -0.50 | 0.57% | -129.02% | |||
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% |
Compare CRIS vs Peers
Curis, Inc. (CRIS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRIS Income Statement
Curis, Inc. (CRIS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 9.9M | 10.43M | 10M | 10.84M | 10.65M | 10.16M | 10.02M | 10.91M | 9.44M | 7.06M |
Revenue Growth % | 31.5% | 5.35% | -4.07% | 8.31% | -1.72% | -4.57% | -1.37% | 8.83% | -13.43% | -36.95% |
Cost of Goods Sold | 496K | 563K | 503K | 534K | 533K | 257K | 212K | 98K | 45K | 39K |
COGS % of Revenue | 5.01% | 5.4% | 5.03% | 4.93% | 5.01% | 2.53% | 2.12% | 0.9% | 0.48% | - |
Gross Profit | 9.4M▲ 0% | 9.87M▲ 4.9% | 9.5M▼ 3.7% | 10.3M▲ 8.4% | 10.12M▼ 1.8% | 9.9M▼ 2.1% | 9.81M▼ 0.9% | 10.81M▲ 10.2% | 9.4M▼ 13.1% | 7.02M▲ 0% |
Gross Margin % | 94.99% | 94.6% | 94.97% | 95.07% | 94.99% | 97.47% | 97.88% | 99.1% | 99.52% | 99.45% |
Gross Profit Growth % | 31.9% | 4.92% | -3.69% | 8.42% | -1.8% | -2.09% | -0.95% | 10.18% | -13.06% | - |
Operating Expenses | 59.16M | 39.2M | 33.86M | 35.2M | 52.18M | 62.92M | 58.14M | 55.35M | 42.34M | 41.29M |
OpEx % of Revenue | 597.72% | 375.89% | 338.43% | 324.86% | 490.01% | 619.22% | 580.1% | 507.44% | 448.43% | - |
Selling, General & Admin | 25.82M | 14.79M | 11.55M | 12.13M | 17.3M | 19.65M | 18.65M | 16.79M | 14.05M | 15.12M |
SG&A % of Revenue | 260.84% | 141.78% | 115.5% | 111.96% | 162.43% | 193.35% | 186.04% | 153.92% | 148.75% | - |
Research & Development | 33.34M | 24.41M | 22.3M | 23.07M | 34.88M | 43.28M | 39.5M | 38.56M | 28.25M | 26.16M |
R&D % of Revenue | 336.88% | 234.11% | 222.93% | 212.9% | 327.58% | 425.87% | 394.05% | 353.52% | 299.21% | - |
Other Operating Expenses | -104K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45K | 0 |
Operating Income | -49.76M▲ 0% | -29.33M▲ 41.1% | -24.36M▲ 17.0% | -24.9M▼ 2.2% | -42.06M▼ 68.9% | -53.02M▼ 26.0% | -48.33M▲ 8.8% | -44.54M▲ 7.8% | -32.9M▲ 26.1% | -34.26M▲ 0% |
Operating Margin % | -502.73% | -281.29% | -243.46% | -229.79% | -395.01% | -521.75% | -482.21% | -408.34% | -348.43% | -485.12% |
Operating Income Growth % | 14.26% | 41.05% | 16.97% | -2.23% | -68.95% | -26.04% | 8.84% | 7.84% | 26.13% | - |
EBITDA | -49.52M | -29.16M | -24.23M | -24.75M | -41.91M | -52.79M | -48.08M | -44.34M | -32.73M | -34.14M |
EBITDA Margin % | -500.35% | -279.59% | -242.21% | -228.46% | -393.53% | -519.45% | -479.67% | -406.48% | -346.64% | -483.31% |
EBITDA Growth % | 14.38% | 41.13% | 16.89% | -2.16% | -69.29% | -25.96% | 8.92% | 7.78% | 26.18% | 18.79% |
D&A (Non-Cash Add-back) | 235K | 177K | 125K | 144K | 158K | 233K | 255K | 203K | 169K | 128K |
EBIT | -49.35M | -28.65M | -27.3M | -24.81M | -40.96M | -51.9M | -45.39M | -42.77M | -5.4M | -7.56M |
Net Interest Income | -3.45M | -3.24M | -4.23M | -5.03M | -4.26M | -3.65M | 919K | 1.15M | -1.87M | 300K |
Interest Income | 513K | 684K | 614K | 63K | 211K | 1.12M | 2.94M | 1.77M | 316K | 300K |
Interest Expense | 3.97M | 3.93M | 4.85M | 5.09M | 4.47M | 4.77M | 2.02M | 615K | 2.19M | 0 |
Other Income/Expense | -3.56M | -3.24M | -7.79M | -5.01M | -3.37M | -3.65M | 919K | 1.15M | 25.32M | 13.1M |
Pretax Income | -53.32M▲ 0% | -32.58M▲ 38.9% | -32.14M▲ 1.3% | -29.91M▲ 6.9% | -45.44M▼ 51.9% | -56.67M▼ 24.7% | -47.41M▲ 16.3% | -43.39M▲ 8.5% | -7.58M▲ 82.5% | -21.16M▲ 0% |
Pretax Margin % | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% | -299.66% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -53.32M▲ 0% | -32.58M▲ 38.9% | -32.14M▲ 1.3% | -29.91M▲ 6.9% | -45.44M▼ 51.9% | -56.67M▼ 24.7% | -47.41M▲ 16.3% | -43.39M▲ 8.5% | -7.58M▲ 82.5% | -21.16M▲ 0% |
Net Margin % | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% | -299.66% |
Net Income Growth % | 11.74% | 38.9% | 1.33% | 6.95% | -51.92% | -24.73% | 16.34% | 8.49% | 82.53% | 49.76% |
Net Income (Continuing) | -53.32M | -32.58M | -32.14M | -29.91M | -45.44M | -56.67M | -47.41M | -43.39M | -7.58M | -21.16M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -35.75▲ 0% | -19.67▲ 45.0% | -19.37▲ 1.5% | -12.29▲ 36.6% | -9.92▲ 19.3% | -12.14▼ 22.4% | -8.96▲ 26.2% | -6.88▲ 23.2% | -0.58▲ 91.6% | -0.11▲ 0% |
EPS Growth % | 21.43% | 44.98% | 1.53% | 36.55% | 19.28% | -22.38% | 26.19% | 23.21% | 91.57% | 80.9% |
EPS (Basic) | -35.75 | -19.67 | -19.37 | -12.29 | -9.92 | -12.14 | -8.96 | -6.88 | -0.58 | - |
Diluted Shares Outstanding | 1.49M | 1.66M | 1.66M | 2.43M | 4.58M | 4.67M | 5.29M | 6.31M | 131.64M | 193.63M |
Basic Shares Outstanding | 1.49M | 1.66M | 1.66M | 2.43M | 4.58M | 4.67M | 5.29M | 6.31M | 131.64M | 193.63M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CRIS Balance Sheet
Curis, Inc. (CRIS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 64.29M | 27.13M | 25M | 172.75M | 122.38M | 92.12M | 60.91M | 26.39M | 6.92M | 15M |
Cash & Short-Term Investments | 60.23M | 24.27M | 20.54M | 168.49M | 115.88M | 85.62M | 56.33M | 20M | 5.06M | 15M |
Cash Only | 38.29M | 23.64M | 15.43M | 129.61M | 40.01M | 19.66M | 26.68M | 20M | 5.06M | 15M |
Short-Term Investments | 21.94M | 634K | 5.11M | 38.88M | 75.87M | 65.97M | 29.65M | 0 | 0 | 0 |
Accounts Receivable | 3.07M | 2.86M | 3.24M | 3.04M | 3.22M | 2.98M | 2.79M | 3.35M | 0 | 0 |
Days Sales Outstanding | 113.32 | 100.25 | 118.36 | 102.51 | 110.5 | 106.86 | 101.75 | 112.06 | - | 77.45 |
Inventory | 0 | -827K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 153K | 0 | 0 | 3.52M | 1.78M | 3.04M | 1.85M | 0 |
Total Non-Current Assets | 9.5M | 10.23M | 10.1M | 31.61M | 39.93M | 16.73M | 16.37M | 14.88M | 13.05M | 11.93M |
Property, Plant & Equipment | 366K | 267K | 303K | 7.24M | 6.25M | 5.09M | 3.49M | 3.39M | 1.95M | 2.94M |
Fixed Asset Turnover | 27.04x | 39.06x | 33.02x | 1.50x | 1.70x | 2.00x | 2.87x | 3.21x | 4.84x | 2.86x |
Goodwill | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 153K | 153K | 0 | 14.56M | 23.96M | 0 | 0 | 544K | 0 | 544K |
Other Non-Current Assets | 156K | 982K | 819K | 819K | 726K | 2.66M | 3.9M | 1.96M | 2.12M | -544K |
Total Assets | 73.8M▲ 0% | 37.37M▼ 49.4% | 35.11M▼ 6.0% | 204.36M▲ 482.1% | 162.3M▼ 20.6% | 108.85M▼ 32.9% | 77.28M▼ 29.0% | 41.27M▼ 46.6% | 19.97M▼ 51.6% | 29.69M▲ 0% |
Asset Turnover | 0.13x | 0.28x | 0.28x | 0.05x | 0.07x | 0.09x | 0.13x | 0.26x | 0.47x | 0.27x |
Asset Growth % | 27.78% | -49.37% | -6.04% | 482.1% | -20.58% | -32.93% | -29% | -46.6% | -51.62% | -153.06% |
Total Current Liabilities | 14.1M | 6.38M | 6.54M | 10.08M | 13.44M | 10.01M | 22.02M | 19.03M | 14.08M | 14.97M |
Accounts Payable | 5.42M | 2.91M | 4.46M | 4.17M | 6.42M | 3.19M | 3.17M | 3.02M | 5.61M | 6.74M |
Days Payables Outstanding | 3.99K | 1.89K | 3.24K | 2.85K | 4.39K | 4.53K | 5.46K | 11.26K | 45.52K | 48.89K |
Short-Term Debt | 5.89M | 6.88M | 0 | 557K | 0 | 0 | 0 | 0 | 0 | 1.23M |
Deferred Revenue (Current) | 0 | -6.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 606K | 683K | 1.41M | 2.64M | 3.26M | 0 | 8.5M | 7.56M | 0 | 7M |
Current Ratio | 4.56x | 4.25x | 3.82x | 17.14x | 9.11x | 9.20x | 2.77x | 1.39x | 0.49x | 1.00x |
Quick Ratio | 4.56x | 4.38x | 3.82x | 17.14x | 9.11x | 9.20x | 2.77x | 1.39x | 0.49x | 1.00x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -48.81K |
Total Non-Current Liabilities | 35.7M | 35.48M | 62.48M | 63.61M | 58.16M | 52.28M | 35.59M | 28.24M | 428K | 2M |
Long-Term Debt | 35.67M | 28.6M | 0 | 334K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 5.04M | 4.36M | 2.8M | 1.49M | 1.62M | 428K | 2.32M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 34K | 11K | 62.48M | 58.23M | 53.8M | 49.48M | 34.1M | 26.62M | 0 | 1.9M |
Total Liabilities | 49.8M | 41.86M | 69.02M | 73.69M | 71.59M | 62.3M | 57.61M | 47.26M | 14.5M | 16.98M |
Total Debt | 41.55M | 35.48M | 166K | 7.66M | 5.04M | 3.94M | 2.79M | 2.95M | 1.62M | 1.34M |
Net Debt | 3.27M | 11.85M | -15.26M | -121.95M | -34.97M | -15.72M | -23.89M | -17.04M | -3.44M | -13.66M |
Debt / Equity | 1.73x | - | - | 0.06x | 0.06x | 0.08x | 0.14x | - | 0.30x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.40x |
Interest Coverage | -12.44x | -7.30x | -5.63x | -4.87x | -9.16x | -10.88x | -22.48x | -69.55x | -2.47x | - |
Total Equity | 23.99M▲ 0% | -4.5M▼ 118.7% | -33.91M▼ 654.2% | 130.67M▲ 485.3% | 90.71M▼ 30.6% | 46.55M▼ 48.7% | 19.67M▼ 57.7% | -6M▼ 130.5% | 5.46M▲ 191.1% | 12.71M▲ 0% |
Equity Growth % | -18.02% | -118.74% | -654.25% | 485.33% | -30.58% | -48.68% | -57.75% | -130.49% | 191.06% | -1500.07% |
Book Value per Share | 16.09 | -2.72 | -20.44 | 53.70 | 19.81 | 9.97 | 3.72 | -0.95 | 0.04 | 0.07 |
Total Shareholders' Equity | 23.99M | -4.5M | -33.91M | 130.67M | 90.71M | 46.55M | 19.67M | -6M | 5.46M | 12.71M |
Common Stock | 1.65M | 332K | 332K | 915K | 916K | 48K | 59K | 85K | 129K | 400K |
Retained Earnings | -952.26M | -984.84M | -1.02B | -1.05B | -1.09B | -1.15B | -1.2B | -1.24B | -1.25B | -1.27B |
Treasury Stock | -1.52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2K | 0 | 0 | -3K | -109K | -186K | 229K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRIS Cash Flow Statement
Curis, Inc. (CRIS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -48.35M | -30.07M | -26.2M | -25.74M | -37.62M | -54.34M | -38.43M | -39.56M | -27.2M | -28.95M |
Operating CF Margin % | -488.53% | -288.31% | -261.95% | -237.55% | -353.26% | -534.71% | -383.46% | -362.7% | -288.05% | - |
Operating CF Growth % | -35.03% | 37.82% | 12.84% | 1.78% | -46.16% | -44.44% | 29.27% | -2.94% | 31.25% | 41.34% |
Net Income | -53.32M | -32.58M | -32.14M | -29.91M | -45.44M | -56.67M | -47.41M | -43.39M | -7.58M | -21.16M |
Depreciation & Amortization | 235K | 177K | 125K | 144K | 158K | 1.39M | 255K | 187K | 169K | 118K |
Stock-Based Compensation | 5.36M | 3.94M | 2.66M | 2.7M | 5.28M | 0 | 6M | 5.93M | 4.02M | 2.85M |
Deferred Taxes | 0 | 7K | 0 | 24K | 1.4M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 91K | -112K | 4.71M | 255K | -26K | 7.76M | -55K | 1.43M | -25.56M | -10.79M |
Working Capital Changes | -723K | -1.5M | -1.56M | 1.05M | 1M | -6.82M | 2.78M | -3.72M | 1.75M | 30K |
Change in Receivables | -614K | 209K | -380K | 201K | -181K | 249K | 181K | -555K | -1.03M | -2.07M |
Change in Inventory | -49.92M | 1.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -376K | -1.87M | 60K | 1M | 4.96M | -3.88M | 3.34M | -2.08M | 2.55M | 2.78M |
Cash from Investing | -3.63M | 21.37M | -4.46M | -49.05M | -47.9M | 33.02M | 37.79M | 29.44M | 2.5M | 2.5M |
Capital Expenditures | -188K | -85K | -41K | -677K | 0 | -416K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 1.9% | 0.82% | 0.41% | 6.25% | - | 4.09% | - | - | - | 0% |
Acquisitions | 188K | 85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -188K | -85K | 0 | 0 | 0 | 0 | 0 | 0 | 2.5M | 2.5M |
Cash from Financing | 64.23M | -5.96M | 23.27M | 188.81M | -4.17M | 867K | 7.58M | 3.44M | 9.77M | 21.17M |
Debt Issued (Net) | 21.74M | -6.1M | 23.2M | 891K | 0 | -4.97M | 0 | -8.59M | -5.59M | -3.12M |
Equity Issued (Net) | 41.55M | 0 | 68K | 193.22M | 300K | 5.84M | 14.12M | 12.02M | 15.35M | 24.29M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 946K | 143K | 0 | -5.3M | -4.47M | 0 | -6.54M | 0 | 0 | 0 |
Net Change in Cash | 12.25M▲ 0% | -14.65M▼ 219.6% | -8.05M▲ 45.0% | 114.03M▲ 1516.0% | -89.69M▼ 178.7% | -20.36M▲ 77.3% | 6.93M▲ 134.1% | -6.68M▼ 196.4% | -14.94M▼ 123.5% | -5.28M▲ 0% |
Free Cash Flow | -48.54M▲ 0% | -30.15M▲ 37.9% | -26.25M▲ 12.9% | -26.42M▼ 0.6% | -37.62M▼ 42.4% | -54.75M▼ 45.5% | -38.43M▲ 29.8% | -39.56M▼ 2.9% | -27.2M▲ 31.2% | -28.95M▲ 0% |
FCF Margin % | -490.43% | -289.13% | -262.36% | -243.8% | -353.26% | -538.8% | -383.46% | -362.7% | -288.05% | -409.88% |
FCF Growth % | -34.32% | 37.89% | 12.95% | -0.65% | -42.41% | -45.55% | 29.8% | -2.94% | 31.25% | 13.8% |
FCF per Share | -32.55 | -18.21 | -15.82 | -10.86 | -8.22 | -11.73 | -7.26 | -6.27 | -0.21 | -0.15 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.92x | 0.82x | 0.86x | 0.83x | 0.96x | 0.81x | 0.91x | 3.59x | 1.37x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRIS Key Ratios
Curis, Inc. (CRIS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -200.22% | -334.15% | - | -61.82% | -41.05% | -82.58% | -143.19% | -634.71% | -138.81% | 805.67% |
Return on Invested Capital (ROIC) | -148.25% | -127.12% | - | - | -97.89% | -91.87% | -272.36% | - | - | 241.71% |
Gross Margin | 94.99% | 94.6% | 94.97% | 95.07% | 94.99% | 97.47% | 97.88% | 99.1% | 99.52% | 99.45% |
Net Margin | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% | -299.66% |
Debt / Equity | 1.73x | - | - | 0.06x | 0.06x | 0.08x | 0.14x | - | 0.30x | 0.11x |
Interest Coverage | -12.44x | -7.30x | -5.63x | -4.87x | -9.16x | -10.88x | -22.48x | -69.55x | -2.47x | - |
FCF Conversion | 0.91x | 0.92x | 0.82x | 0.86x | 0.83x | 0.96x | 0.81x | 0.91x | 3.59x | 1.37x |
Revenue Growth | 31.5% | 5.35% | -4.07% | 8.31% | -1.72% | -4.57% | -1.37% | 8.83% | -13.43% | -36.95% |
Related:CRIS Dividend History·CRIS Revenue History·CRIS Price History·CRIS P/E History·CRIS Financial Ratios·CRIS Institutional Holders
CRIS SEC Filings & Documents
Curis, Inc. (CRIS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRIS Frequently Asked Questions
Curis, Inc. (CRIS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Curis, Inc. (CRIS) reported $7.1M in revenue for fiscal year 2025. This represents a 120% increase from $3.2M in 1999.
Curis, Inc. (CRIS) saw revenue decline by 13.4% over the past year.
Curis, Inc. (CRIS) reported a net loss of $21.2M for fiscal year 2025.
Dividend & Returns
Curis, Inc. (CRIS) has a return on equity (ROE) of -138.8%. Negative ROE indicates the company is unprofitable.
Curis, Inc. (CRIS) had negative free cash flow of $28.9M in fiscal year 2025, likely due to heavy capital investments.